



## Two new spliceostatin analogs from the strain *Pseudomonas* sp. HS-NF-1408

Yue Zhao<sup>1</sup> · Junwei Zhao<sup>1</sup> · Chang Lu<sup>1</sup> · Hui Zhang<sup>2</sup> · Huan Qi<sup>2</sup> · Shanwen Jiang<sup>1</sup> · Xiaowei Guo<sup>1</sup> · Jidong Wang<sup>2</sup> · Wensheng Xiang<sup>1</sup>

Received: 20 December 2017 / Revised: 3 March 2018 / Accepted: 7 March 2018 / Published online: 17 April 2018  
© The Author(s) under exclusive licence to the Japan Antibiotics Research Association 2018

### Abstract

Two new spliceostatin derivatives, designed as spliceostatin H (**1**) and spliceostatin I (**2**), and one known compound FR901464 (**3**), were isolated from the strain *Pseudomonas* sp. HS-NF-1408. Their structures were determined by the comprehensive spectroscopic data, including 1D, 2D NMR, MS spectral analysis and comparison with data from the literature. Compound **1** exhibited potent cytotoxicity activity against A549 and HepG2 with IC<sub>50</sub> values of 3.57 and 16.72 µg/ml, respectively.

The spliceostatin class of natural products, which has two highly functionalized tetrahydropyran rings linked by a diene chain, was reported to be potent cytotoxic agents via inhibition of the spliceosome, a key–protein complex in the biosynthesis of mature mRNA [1–3]. Due to the interesting architecture and biological activity, many natural and synthetic spliceostatin compounds have been described with the aim of discovering more potent drug leads [4–8]. In our ongoing effort to exploit novel bioactive compounds from microbial sources, the strain *Pseudomonas* sp. HS-NF-1408 obtained from a soil sample was selected for further study because of its cytotoxic activity against A549 and HepG2. As a result, two new members of the spliceostatins group, designed as spliceostatin H (**1**), spliceostatin I (**2**), and the known compound FR901464 (**3**) (Fig. 1), were isolated from the strain *Pseudomonas* sp. HS-NF-1408. In this paper, the details of fermentation, isolation, structure

determination, and biological activity of two new derivatives are described.

The producing strain *Pseudomonas* sp. HS-NF-1408 was isolated from a soil sample collected from the Qingshan lake, located in Lin'an, Zhejiang province, China. The strain was identified as the genus *Pseudomonas* because its 16S rRNA sequence (accession no: MG386199 in the GenBank) showed a high similarity of 99% with that of the *Pseudomonas chlororaphis* strain XF10 (accession no: MF121986.1 in the GenBank) and it was deposited in the Pharmaceutical Research Culture Collection, Zhejiang Hisun Group Co. Ltd. with accession no: HS-NF-1408.

This strain was grown on an agar slant containing 30 g beef extract, 5 g peptone, and 15 g agar in 1.0 l of water, pH 7.0–7.2 and incubated for 6–7 days at 28 °C. The strain of stock culture was inoculated into 100 1.0 l Erlenmeyer flasks containing 36% volume of the seed medium at 30 °C for 24 h, shaken at 220 r.p.m. The seed medium consisted of polypeptone 1%, yeast extract 0.5%, and NaCl 0.5% in 1.0 l water, pH 7.0–7.2. All the media were sterilized at 121 °C for 20 min. Then, the entire culture was transferred into a 500 l fermentor containing 300 l of production medium consisting of defatted soybean meal 1%, corn steep liquor 0.5%, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 0.2%, soluble starch 1%, glycerin 1%, glucose 0.5%, MgSO<sub>4</sub>·7H<sub>2</sub>O 0.0006%, CaCO<sub>3</sub> 0.2%, adecanol LG-109 0.05%, and silicon KM-70 0.05% at pH 7.0–7.2. The fermentation was carried out at 28 °C for 6 days stirred at 220 r.p.m. with an aeration rate of 18,000 l of air per hour.

These authors contributed equally: Yue Zhao, Junwei Zhao.


**Electronic supplementary material** The online version of this article (<https://doi.org/10.1038/s41429-018-0052-0>) contains supplementary material, which is available to authorized users.

✉ Wensheng Xiang  
xiangwensheng@neau.edu.cn

<sup>1</sup> Life Science and Biotechnology Research Center, School of Life Science, Northeast Agricultural University, Harbin, China

<sup>2</sup> Department of New Drug Screening, Zhejiang Hisun Pharmaceutical Co., Ltd, Taizhou, China

**Fig. 1** Structures of compounds 1, 2 and 3



The final 300 l of broth from 500 l fermentor was filtered to separate mycelial cake and supernatant. The mycelial cake was extracted with MeOH (50 l) and the supernatant was subjected to a Diaion HP-20 resin (Mitsubishi Chemical, Tokyo, Japan) column eluting with 95% EtOH (50 l). The MeOH extract and the EtOH eluents were evaporated under reduced pressure to yield the crude extract. The crude extract was chromatographed on a silica gel (Qingdao Haiyang Chemical Group, Qingdao, China; 100–200 mesh) column and successively eluted with a stepwise gradient of CHCl<sub>3</sub>/MeOH (100:0-50:50, v-v) to give five fractions (Fr.1-Fr.5) based on the TLC profiles. Fr.2 was subjected to another silica gel column eluted with n-hexane/acetone (95:5-50:50, v:v) to give three fractions (Fr.2-1 to Fr.2-3). Fr.2-1 was further isolated by preparative HPLC (Shimadzu LC-8A, Shimadzu-C18, 5 μm, 250 × 20 mm<sup>2</sup> inner diameter; 20 ml/min; 220/254 nm; Shimadzu, Kyoto, Japan) eluting with a stepwise gradient MeOH/H<sub>2</sub>O (50–100%, v/v, 40 min) to obtain five subfractions (Fr.2-1-1 to Fr.2-1-5) based on the retention times. Then, Fr.2-1-1 (*t*<sub>R</sub> 10.6 min) was purified by semi-preparative HPLC (Agilent 1100, Zorbax SB-C18, 5 μm, 9.4 × 250 mm<sup>2</sup> inner diameter; 1.5 ml/min; 254 nm; Agilent, Palo Alto, CA, USA) eluting with CH<sub>3</sub>CN:H<sub>2</sub>O (50:50, v:v) to obtain spliceostatin H (**1**) (*t*<sub>R</sub> 8.4 min, 30 mg). Fr.2-1-2 (*t*<sub>R</sub> 12.1 min) was separated by semi-preparative HPLC eluting with CH<sub>3</sub>CN:H<sub>2</sub>O (40:60, v:v) to yield FR901464 (**3**) (*t*<sub>R</sub> 12.1 min, 63 mg). Fr.2-1-4 (*t*<sub>R</sub> 16.7 min) was isolated by semi-preparative HPLC eluting with CH<sub>3</sub>CN:H<sub>2</sub>O (50:50, v:v) to give spliceostatin I (**2**) (*t*<sub>R</sub> 16.9 min, 6.3 mg). <sup>1</sup>H and <sup>13</sup>C NMR spectra were measured with a Bruker DRX-400 (400 MHz for <sup>1</sup>H and 100

MHz for <sup>13</sup>C) spectrometer (Bruker, Rheinstetten, Germany). The ESIMS and HRESIMS spectra were taken on a Q-TOF Micro LC-MS-MS mass spectrometer (Waters Co, Milford, MA, USA).

Compound **1** was isolated as colorless oil with [α]<sub>D</sub><sup>20</sup> -60 (c 0.02, EtOH) and UV (EtOH) λ<sub>max</sub> nm (log ε): 236 (4.54). Its molecular formula was determined to be C<sub>27</sub>H<sub>43</sub>NO<sub>9</sub> by HRESIMS at *m/z* 548.2825 [M + Na]<sup>+</sup> (calcd as 548.2830 for C<sub>27</sub>H<sub>43</sub>NO<sub>9</sub>Na) and NMR data (Table 1). The IR spectrum showed absorption bands for hydroxyl (3369 cm<sup>-1</sup>) and carbonyl (1732 cm<sup>-1</sup>) functionalities. The <sup>1</sup>H NMR spectrum of **1** (Table 1) displayed three doublet methyls at δ<sub>H</sub> 1.04 (*J* = 7.3 Hz), 1.16 (*J* = 6.4 Hz) and 1.37 (*J* = 6.5 Hz), a singlet methyl at δ<sub>H</sub> 1.39, an olefinic methyl at δ<sub>H</sub> 1.81, an acetyl methyl at δ<sub>H</sub> 2.04, seven methine proton signals from δ<sub>H</sub> 3.30 to δ<sub>H</sub> 4.39 and six downfield proton signals from δ<sub>H</sub> 5.50 to δ<sub>H</sub> 6.42. The <sup>13</sup>C NMR spectrum (Table 1) exhibited 27 resonances ascribed to six methyls at δ<sub>C</sub> 12.7, 14.9, 18.0, 20.3, 21.1, 29.1, four methylenes (one oxygenated) at δ<sub>C</sub> 33.1, 36.9, 41.7, 66.8, seven *sp*<sup>3</sup> methines (five oxygenated) at δ<sub>C</sub> 30.6, 48.6, 70.0, 71.7, 71.8, 76.7, 82.2, one hemiketal carbon at δ<sub>C</sub> 97.8, one oxygen-bearing quaternary *sp*<sup>3</sup> carbon at δ<sub>C</sub> 74.8, five *sp*<sup>2</sup> methines at δ<sub>C</sub> 123.4, 126.3, 129.8, 138.7, 144.8, one *sp*<sup>2</sup> quaternary carbon at δ<sub>C</sub> 135.9 and two carbonyls at δ<sub>C</sub> 167.5, 172.2. The <sup>1</sup>H and <sup>13</sup>C NMR data of **1** closely resembled those of **NP6**<sup>9</sup> except for the presence of a methylene carbon at δ<sub>H</sub> 1.83, 1.90/δ<sub>C</sub> 41.7 in **1** instead of the corresponding oxygenated methine (C-2) in **NP6**. The HMBC correlations (Fig. 2) from δ<sub>H</sub> 1.39 (H<sub>3</sub>-17) and δ<sub>H</sub> 3.39, 3.57 (H<sub>2</sub>-18) to this carbon supported this assignment.

**Table 1**  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of compounds **1** (in  $\text{CD}_3\text{OD}$ ), **2** and **3** (both in  $\text{CDCl}_3$ )


Position	$\delta_{\text{H}}$ (ppm, $J$ in Hz)			$\delta_{\text{C}}$ (ppm)		
	1	2	3	1	2	3
1		4.42 m		97.8 (s)	70.2 (d)	96.4 (s)
2	1.83 d (14.2) 1.90 d (14.2)	1.85 dd (12.1, 5.9) 1.54 brd (12.1)	1.71 d (14.1) 2.37 d (14.1)	41.7 (t)	36.9 (t)	41.5 (t)
3				74.8 (s)	76.0 (s)	57.7 (s)
4	3.33 m	1.62 m	3.64 d (9.9)	71.7 (d)	40.2 (t)	67.8 (d)
5	4.36 dd (9.2, 6.8)	4.53 m	4.35 m	71.8 (d)	68.9 (d)	73.5 (d)
6	5.69 dd (15.3, 6.8)	5.53 m	5.70 dd (15.7, 7.0)	126.3 (d)	128.5 (d)	123.8 (d)
7	6.40 d (15.3)	6.29 d (15.8)	6.43 d (15.7)	138.7 (d)	136.8 (q)	138.5 (d)
8				135.9 (s)	135.7 (s)	134.6 (s)
9	5.54 t (6.7)	5.51 m	5.52 t (6.8)	129.8 (d)	129.9 (d)	129.2 (d)
10	2.28 m 2.41 m	2.24 m 2.38 m	2.27 m 2.40 m	33.1 (t)	33.1 (t)	32.0 (t)
11	3.59 m	3.56 m	3.53 m	82.2 (d)	82.2 (d)	80.9 (d)
12	1.75 m	1.72 m	1.80 m	30.6 (d)	30.6 (d)	29.0 (d)
13	1.96 m	1.94 m	1.96 m	36.9 (t)	36.9 (t)	35.9 (t)
14	3.77 m	3.74 m	3.95 brd (7.8)	48.6 (d)	48.6 (d)	47.1 (d)
15	3.72 m	3.70 m	3.67 m	76.7 (d)	76.7 (d)	76.0 (d)
16	1.16 d (6.4)	1.14 d (16.4)	1.16 d (7.8)	18.0 (q)	18.1 (q)	17.8 (q)
17	1.39 s	3.10 dd (15.3, 9.4) 2.63 dd (15.3, 5.1)	1.51 s	29.1 (q)	40.0 (t)	29.0 (q)
18	3.57 d (10.8) 3.39 d (10.8)	3.23 d (9.5) 3.26 d (9.5)	2.60 d (4.4) 3.13 d (4.4)	66.8 (t)	79.7(t)	47.8 (t)
19	1.81 brs	1.75 brs	1.80 brs	12.7 (q)	12.7 (q)	12.6 (q)
20	1.04 d (7.3)	1.02 d (7.3)	1.03 d (7.3)	14.9 (q)	14.9 (q)	15.0 (q)
21					175.8 (s)	
22		3.50 q (7.0)			68.0 (t)	
23		1.19 t (7.0)			15.4 (q)	
1'				167.5 (s)	167.5 (s)	164.9 (s)
2'	6.01 d (11.8)	5.98 d (11.8)	5.73 d (11.5)	123.4 (d)	123.4 (d)	122.5 (d)
3'	5.96 dd (11.8, 8.0)	5.95 dd (11.8, 7.3)	5.91 dd (11.5, 7.9)	144.8 (d)	144.8 (d)	143.6 (d)
4'	6.38 m	6.36 m	6.28 m	70.0 (d)	70.0 (d)	68.9 (d)
5'	1.37 d (6.5)	1.34 d (6.4)	1.40 d (6.5)	20.3 (q)	20.3 (q)	20.0 (q)
1''				172.2 (s)	172.2 (s)	170.4 (s)
2''	2.04 s	2.01 s	2.06 s	21.1 (q)	21.1 (q)	21.2 (q)

Thus, the gross structure of **1** was established to be a 2-dehydroxy derivative of **NP6**, as shown in Fig. 1. The  $^1\text{H}$ - $^1\text{H}$  COSY correlations (Fig. 2) of H-4/H-5/H-6/H-7, H-9/H<sub>2</sub>-10/H-11/H-12/H<sub>2</sub>-13/H-14/H-15/H<sub>3</sub>-16, H-12/H<sub>3</sub>-20, H-2'/H-3'/H-4'/H<sub>3</sub>-5' and the observed HMBC cross-peaks from H<sub>3</sub>-17 to C-1, from H<sub>2</sub>-18 to C-3 and C-4, from H<sub>3</sub>-19 to C-7, C-8, and C-9, from H<sub>3</sub>-2'' and H-4' to C-1'' further confirmed the above structural assignment. In **1**, the coupling constants of H-7 ( $\delta_{\text{H}}$ 6.40, d,  $J$  = 15.3 Hz) and H-2' ( $\delta_{\text{H}}$ 6.01, d,  $J$  = 11.8 Hz) unambiguously revealed the double bond geometry at C-6 and C-2' to be *trans* and *cis*, respectively. In the NOESY spectrum, the NOE correlations (Fig. 2) between H-7 and H-9 indicated the double bond at


C-8 was *trans*. In addition, the relative configuration for H-4 and H-5 was *anti* based on the  $J$  value between H-4/H-5 (9.2 Hz). The relative stereochemistry of **1** was assigned to be the same as that of FR901464 [8]. The NOE cross peaks from H<sub>2</sub>-10 to H<sub>3</sub>-20 and from H-4 to H<sub>2</sub>-18 further supported the assignment. From this finding, the structure of **1** was established and named as spliceostatin H. All NMR spectra data of compound **1** are present in Supplementary file (Figure S1–S10).

Compound **2** was isolated as colorless oil with  $[\alpha]_{\text{D}}^{25}$  (c 0.02, EtOH) and UV (EtOH)  $\lambda_{\text{max}}$  nm (log  $\epsilon$ ): 235 (4.42). Its molecular formula was established as  $\text{C}_{30}\text{H}_{47}\text{NO}_9$  by HRESIMS at  $m/z$  566.3320  $[\text{M} + \text{H}]^+$  (calcd as 566.3324

**Fig. 2** Key  $^1\text{H}$ - $^1\text{H}$  COSY, HMBC, and NOESY correlations of spliceostatin H (**2**)



**Fig. 3** Key  $^1\text{H}$ - $^1\text{H}$  COSY, HMBC, and NOESY correlations of spliceostatin I (**2**)



**Table 2** Cytotoxic activity of compounds **1**, **2** and **3** against selected human tumor cell lines

Compound	IC <sub>50</sub> (μg/ml)			
	1	2	3	doxorubicin
HepG2	16.72	101.93	0.50	0.58
A549	3.57	25.81	0.09	0.12

for  $\text{C}_{30}\text{H}_{48}\text{NO}_9$ ) and NMR data (Table 1), requiring  $8^\circ$  of unsaturation. The IR absorption bands at  $3431\text{ cm}^{-1}$ ,  $1724\text{ cm}^{-1}$  were characteristics of hydroxyl and carbonyl groups. The  $^1\text{H}$  NMR data (Table 1) of **2** displayed three doublet methyls ( $\delta_{\text{H}}$  1.02, 1.14, 1.34), one triplet methyl ( $\delta_{\text{H}}$  1.19), an olefinic methyl ( $\delta_{\text{H}}$  1.75) and an acetyl methyl ( $\delta_{\text{H}}$  2.01). The  $^{13}\text{C}$  NMR data (Table 1) showed resonances for 30 carbons, which included six methyls, three double bonds, seven  $sp^3$  methylenes (including two oxygenated at  $\delta_{\text{C}}$  68.0 and 79.7), seven  $sp^3$  methines (five oxygenated), three carbonyls and one oxygen-bearing quaternary carbon ( $\delta_{\text{C}}$  76.0). Comparison of the NMR spectroscopic data and analyses of the 2D NMR spectra revealed the gross structure of **2** to be closely related to **NP7** [9] except for the absence of an acetyl group and the presence of one ethyl group ( $\delta_{\text{H}}/\delta_{\text{C}}$  1.19/15.4, and 3.50/68.0) in **2**. The ethyl group was connected with the C-18 methylene via an oxygen

atom, as evident from the methylene protons ( $\delta_{\text{H}}$  3.50) of the ethyl moiety exhibiting HMBC correlations (Fig. 3) to C-18 ( $\delta_{\text{C}}$  79.7). The large coupling constant of H-7 ( $\delta_{\text{H}}$  6.29,  $J = 15.8\text{ Hz}$ ) and the NOE correlation (Fig. 3) between H<sub>3</sub>-19 and H<sub>2</sub>-10 indicated that the geometry of the two double bond at C-6 and C-8 were all *trans*. The coupling constant of H-2' ( $\delta_{\text{H}}$  5.98, d,  $J = 11.8\text{ Hz}$ ) revealed the double bond at C-2' was *cis*. The cross peaks between H-5 and H<sub>2</sub>-17 in NOESY spectrum suggested a 1, 3-diaxial relationship. On the basis of biogenetic considerations, the stereochemistry of other chiral centers was assigned as that of **1** according to the NOE correlations from H<sub>2</sub>-18 to H-4, from H<sub>3</sub>-20 to H<sub>2</sub>-10 and the concurrence with **1**. Therefore, the structure of **2** was established and named as spliceostatin I. The *O*-ethyl group suggested that this compound may be an artifact. So, it was analyzed by HPLC together with the methanol extract of the fermentation broth. The absence of **2** in the extract suggested the ethoxy group was elaborated in the course of the extraction or purification process. All NMR spectra data of compound **2** are present in Supplementary file (Figure S11–S20).

Compound **3** was identified as FR901464 by comparing the NMR spectral data with those reported in literature [8].

The cytotoxicity of compounds **1**, **2** and **3** were assayed for growth-inhibition activity *in vitro* against two human tumor cell lines, human hepatocellular liver carcinoma cells

HepG2 and human lung tumor cells A549 according to the CCK8 colorimetric method as reported in our previous papers [10, 11] using doxorubicin as positive control (Table 2). As a result, compound **1** exhibited cytotoxic activity against the two tumor cell lines and compound **2** only exhibited potent cytotoxic activity against A549 cell lines.

**Acknowledgements** This work was supported in part by grants from the National Natural Youth Science Foundation of China (No. 31701858), Youth innovation talent program for general undergraduate colleges of Heilongjiang Province (UNPYSCT-2017017), the Heilongjiang Postdoctoral Fund (LBH-Z17015) and the ‘Young Talents’ Project of Northeast Agricultural University (17QC14).

### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

### References

1. He HY, et al. Cytotoxic spliceostatins from *Burkholderia* sp. and their semisynthetic analogues. *J Nat Prod*. 2014;77:1864–70.
2. Motoyoshi H, et al. Structure-activity relationship for FR901464: a versatile method for the conversion and preparation of biologically active biotinylated probes. *Biosci Biotechnol Biochem*. 2004;68:2178–82.
3. Eustaquio AS, et al. Spliceostatin hemiketal biosynthesis in *Burkholderia* spp. is catalyzed by an iron/ $\alpha$ -ketoglutarate-dependent dioxygenase. *Proc Natl Acad Sci USA*. 2014;111:3376–85.
4. Albert BJ, et al. Total synthesis, fragmentation studies, and anti-tumor/antiproliferative activities of FR901464 and its low picomolar analogue. *J Am Chem Soc*. 2007;129:2648–59.
5. Liu XY, et al. Isolation and characterization of spliceostatin B, a new analogue of FR901464, from *Pseudomonas* sp. *J Antibiot*. 2013;66:555–8.
6. Osman S, et al. Structure requirement for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. *Chem Eur J*. 2011;17:895–904.
7. Eustaquio AS, et al. Biosynthetic engineering and fermentation media development leads to gram-scale production of spliceostatin natural products in *Burkholderia* sp. *Metab Eng*. 2016;33:67–75.
8. Nakajima H, et al. New antitumor substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465. *J Antibiot*. 1997;50:96–99.
9. Dirico, JK. Spliceostatin analogs. WO 2014/068443 A1 (2014).
10. Wang JD, et al. HS071, a new furan-type cytotoxic metabolite from *Streptomyces* sp. HS-HY-071. *J Antibiot*. 2008;61:623–6.
11. Wang JD, et al. Five new epothilone metabolites from *Sorangium cellulosum* strain So0157-2. *J Antibiot*. 2009;62:483–7.